Perfil
Israel Rios worked as a Director of Clinical Research at Bristol Myers Squibb Co. from 1978 to 1984, then as a Director of Anti Infective Clinical Research at Marion Merrell Dow, Inc. from 1984 to 1993.
He then worked as a Vice President of Oncology Development at Berlex, Inc. from 1993 to 2002, and as a Vice President of Clinical Affairs at Dendreon Corp.
from 2003 to 2005.
Later, he worked as a Chief Medical Officer and SVP of Medical Affairs at SciClone Pharmaceuticals LLC from 2009 to 2012.
Dr. Rios earned a doctorate degree from the Central University of Venezuela.
Antiguos cargos conocidos de Israel Rios.
| Empresas | Cargo | Fin |
|---|---|---|
| SCICLONE PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 06/04/2012 |
| DENDREON CORPORATION | Director Técnico/Científico/I+D | 01/01/2005 |
Berlex, Inc.
 Berlex, Inc. Pharmaceuticals: MajorHealth Technology Berlex, Inc. manufactured pharmaceutical company. It developed novel diagnostics and therapeutics, which address unmet medical needs. It used to researches, develops, manufactures and markets ethical pharmaceuticals in five strategic areas such as female healthcare, diagnostic imaging, dermatology, oncology and therapeutics. The company was headquartered in Wayne, NJ | Corporate Officer/Principal | 01/01/2002 |
| Marion Merrell Dow, Inc. | Corporate Officer/Principal | 01/01/1993 |
| BRISTOL-MYERS SQUIBB COMPANY | Director Técnico/Científico/I+D | 01/01/1984 |
Formación de Israel Rios.
| Central University of Venezuela | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Empresas privadas | 4 |
|---|---|
SciClone Pharmaceuticals LLC
 SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology SciClone Pharmaceuticals LLC was engaged in the development of therapeutic treatment for oncology, infectious diseases, and cardiovascular disorders. It was also offering ZADAXIN for the treatment of hepatitis B, hepatitis C, certain cancers, and used as immune system enhancer, and DC Bead which is used for the novel treatment of liver cancer. The company was founded in 1990 and was headquartered in San Mateo, CA. | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
| Marion Merrell Dow, Inc. | Health Technology |
Berlex, Inc.
Berlex, Inc. Pharmaceuticals: MajorHealth Technology Berlex, Inc. manufactured pharmaceutical company. It developed novel diagnostics and therapeutics, which address unmet medical needs. It used to researches, develops, manufactures and markets ethical pharmaceuticals in five strategic areas such as female healthcare, diagnostic imaging, dermatology, oncology and therapeutics. The company was headquartered in Wayne, NJ | Health Technology |
- Bolsa de valores
- Insiders
- Israel Rios
